The TRISCEND study (NCT04221490) was an early feasibility study to assess the performance and safety of the Edwards’ EVOQUE tricuspid valve replacement system. This prospective, single-arm, multicentre study enrolled 56 patients with symptomatic moderate or greater TR to receive the EVOQUE valve replacement. At 30 days, 47 participants were available for follow-up.
The participants were quite elderly (mean age 79 years) and had severe TR symptomatic (92% graded as severe or greater). Aetiology of TR was deemed functional in 68% of participants, degenerative in 11%, and mixed/other in the remaining 21%. All devices were implanted via right femoral vein access. The primary outcome measure was freedom from device- or procedure-related adverse events within a 30-day time frame. Endpoints were device and procedural success, a reduction in TR, and a composite of major adverse events. Follow-up was planned at 30 days, 6 months, 1 year, and annually for up to 5 years post-procedure.
Dr Susheel Kodali (Columbia University Medical Center, NY, USA) reported the 30-day results from the TRISCEND trial. Of the 47 patients who were followed up, 46 (98%) experienced a reduction in severity of TR to none or trace; 100% achieved a ≥1-grade reduction; and 95% a ≥2-grade reduction in TR severity. Approximately 10% of patients achieved a ≥5-grade reduction in TR at 30 days.
No major adverse events were observed in 77.4% of the participants at 30 days. The most common adverse event was severe bleeding, experienced by 12 (22.6%) of the participants. None of the bleeding events were life-threatening or fatal.
Dr Kodali also noted that echocardiography performed at discharge showed worsening right ventricular function in about 25.5% of patients. At 30 days, this parameter had improved, with right ventricular dysfunction evident in only 4.5% of the participants. This parameter will continue to be monitored at the next scheduled follow-up at 6 months.
Key secondary outcomes included changes from baseline to 30 days in the New York Heart Association (NYHA) class, 6-minute walk test, and the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores. At 30 days, there was a dramatic improvement in NYHA class, and both the 6-minute walk test and KCCQ scores showed significant improvement.
Encouraged by these preliminary results, researchers have now initiated TRISCEND 2 (NCT04482062), a prospective, multicentre, randomised, controlled, pivotal clinical trial that will evaluate the safety and effectiveness of the EVOQUE system with optimal medical therapy compared with optimal medical therapy alone in the treatment of patients with at least severe tricuspid regurgitation.
- Kodali S. Transfemoral Tricuspid Valve Replacement in Patients with Tricuspid Regurgitation: 30-day Results of the TRISCEND Study. ACC 2021 Scientific Session, 15–17 May.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Novel use of ivabradine in reversible cardiomyopathy Next Article
MRI screening for prostate cancer prevents many unnecessary biopsies »
« Novel use of ivabradine in reversible cardiomyopathy Next Article
MRI screening for prostate cancer prevents many unnecessary biopsies »
Table of Contents: ACC 2021
Featured articles
Electrophysiology
Favourable outcomes with transcatheter atrial appendage occlusion
Etripamil nasal spray significantly improves PSVT-related symptoms
Ablation-based rhythm control as effective as rate control in AF and HF
Finerenone reduces the risk of AF onset in patients with CKD and diabetes
Heart Failure and Cardiomyopathy
PARADISE-MI: Sacubitril/valsartan not superior to ramipril in reducing HF events
Older adults with heart failure benefit from rehabilitation programme
Quality improvement intervention fails to improve care for patients with heart failure
Sacubitril/valsartan does not reduce NT-proBNP versus valsartan alone in HFrEF
Novel use of ivabradine in reversible cardiomyopathy
Mavacamten significantly improves QoL of patients with hypertrophic cardiomyopathy
Interventional and Structural Cardiology
Men and women benefit equally from early aspirin withdrawal following PCI
Similar outcomes with fractional flow reserve and angiography-guided revascularisation
TALOS-AMI: Exploring outcomes after switching to clopidogrel versus ticagrelor at 1 month from MI
Clopidogrel monotherapy associated with better net outcomes relative to aspirin monotherapy 6-18 months after PCI
Ischaemic Heart Disease
No difference in ischaemic risk or bleeding with low vs high-dose aspirin for secondary prevention: Lessons and questions from the ADAPTABLE trial
Rivaroxaban reduces total ischaemic events after peripheral artery revascularisation
Moderate hypothermia not superior to mild hypothermia following out-of-hospital cardiac arrest
Better outcomes with invasive strategy if anatomic complete revascularisation is possible
Prevention and Health Promotion
STRENGTH trial fails to demonstrate cardioprotective effect of omega-3 fatty acids
Evinacumab lowers triglyceride levels in severe hypertriglyceridaemia
Health equity and the role of the cardiologist: 7 priorities to consider
COVID-19
Dapagliflozin fails to show a significant protective effect in COVID-19
Therapeutic anticoagulation not superior to prophylactic anticoagulation in COVID-19
Atorvastatin does not reduce mortality in COVID-19
Valvular Heart Disease
Apixaban outcomes similar to current standard of care following TAVR
Preliminary results encouraging for EVOQUE tricuspid valve replacement
Related Articles

July 9, 2021
Novel use of ivabradine in reversible cardiomyopathy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com